Synthesis and biological activity of Akt/PI3K inhibitors

被引：15
|
作者：
Redaelli, C. [1 ]
Granucci, F. [1 ]
De Gioia, L. [1 ]
Cipolla, L. [1 ]
机构：
[1] Univ Milan, Dept Biosci & Biotechnol, I-20126 Milan, Italy
来源：
MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2006年 / 6卷 / 10期
关键词：
kinases; Akt; PI3K; cancer; kinase inhibitors; allosteric inhibitors; phosphatidylinositol; phosphatidylinositol analogues;
D O I：
10.2174/138955706778560139
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Phosphatidylinositol 3-kinase (PI3K) and serine/threonine protein kinase B (PKB or Akt) pathways regulate important cellular processes and are related to a number of human pathologies, such as cancer. The development of kinase inhibitors, with particular attention to small molecule analogues of natural phosphoinositides for pathway interruption and therapeutic applications will be reviewed.
引用
收藏
页码：1127 / 1136
页数：10
相关论文
共 50 条
  • [41] PI3K/AKT signaling and systemic autoimmunity
    Rahul K. Patel
    Chandra Mohan
    Immunologic Research, 2005, 31 : 47 - 55
  • [42] Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
    Gao, Haotian
    Li, Zaolin
    Wang, Kai
    Zhang, Yuhan
    Wang, Tong
    Wang, Fang
    Xu, Youjun
    PHARMACEUTICALS, 2023, 16 (03)
  • [43] PI3K/Akt and apoptosis: size matters
    Thomas F Franke
    Christoph P Hornik
    Lisa Segev
    Grigoriy A Shostak
    Chizuru Sugimoto
    Oncogene, 2003, 22 : 8983 - 8998
  • [44] Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway
    Zapevalova, Maria, V
    Shchegravina, Ekaterina S.
    Fonareva, Irina P.
    Salnikova, Diana, I
    Sorokin, Danila, V
    Scherbakov, Alexander M.
    Maleev, Alexander A.
    Ignatov, Stanislav K.
    Grishin, Ivan D.
    Kuimov, Alexander N.
    Konovalova, Maryia, V
    Svirshchevskaya, Elena, V
    Fedorov, Alexey Yu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [45] Synthesis and Biological Activity of Imidazo[4,5-c]quinoline Derivatives as PI3K/mTOR Inhibitors
    Li Yanjie
    Zhang Xingmin
    Niu Shengxiu
    Zhao Yanping
    Yang Lijuan
    Shao Xiaowei
    Wang Ensi
    CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2017, 33 (06) : 895 - 902
  • [46] Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC
    Yadav, Ravi Prakash
    Chatterjee, Srilagna
    Chatterjee, Arindam
    Pal, Dilip Kumar
    Ghosh, Sudakshina
    Acharya, Krishnendu
    Das, Madhusudan
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2022, 42 (06) : 599 - 607
  • [47] Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
    Janku, Filip
    Hong, David S.
    Fu, Siqing
    Piha-Paul, Sarina A.
    Naing, Aung
    Falchook, Gerald S.
    Tsimberidou, Apostolia M.
    Stepanek, Vanda M.
    Moulder, Stacy L.
    Lee, J. Jack
    Luthra, Rajyalakshmi
    Zinner, Ralph G.
    Broaddus, Russell R.
    Wheler, Jennifer J.
    Kurzrock, Razelle
    CELL REPORTS, 2014, 6 (02): : 377 - 387
  • [48] Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
    Wu, Yi-Hui
    Huang, Yu-Fang
    Chen, Chien-Chin
    Huang, Chia-Yen
    Chou, Cheng-Yang
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [49] The PI3K/Akt pathway: Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors
    Lindsley, Craig W.
    Barnett, Stanley F.
    Layton, Mark E.
    Bilodeau, Mark T.
    CURRENT CANCER DRUG TARGETS, 2008, 8 (01) : 7 - 18
  • [50] The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis
    Xi, Jian-Cheng
    Zang, Hai-Yu
    Guo, Li-Xin
    Xue, Hai-Bin
    Liu, Xiang-Dong
    Bai, Yi-Bing
    Ma, Yuan-Zheng
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2015, 35 (06) : 640 - 645
12345